Introduction
============

Prevalence of resistance of gram-negative bacteria to multiple antibiotics has been reported worldwide. Especially, nosocomial infections such as *Acinetobacter baumannii* are becoming increasingly resistant to carbapenem. The number of occurrences of the same caused by the consumption of carbapenems has increased in hospitals.[@b1-ijgm-10-443]--[@b3-ijgm-10-443]

Antimicrobial drugs worth over 10,000 million baht per year are being consumed in Thailand, leading to tremendous economic loss. The risk factors of developing antibiotic resistance are use of excessive and inappropriate antimicrobial therapy, including a lack of control measures.[@b3-ijgm-10-443],[@b4-ijgm-10-443]

In 2014, it was found that resistance of *A. baumannii* to meropenem was quite high in Lamphun Hospital. Furthermore, consumption of meropenem is extremely costly, which can amount to drug bills worth 1,433,328 baht. In addition, data regarding evaluation of appropriate prescribing of carbapenem in Lamphun Hospital from October 2013 to December 2013 indicated that there was 46.69% of inappropriate prescribing for most indications.

Antimicrobial drug stewardship includes formulary restrictions and preauthorization, prospective audit with intervention, and feedback. Thus, it has been the policy of Lamphun Hospital to use a restriction system for the carbapenem group. This policy was operated in September 2015. This restriction system controls the use of antimicrobial drugs in the wards as a process to solve the issue of antimicrobial resistance even when the hospital has no infectious diseases (ID) specialist. The antimicrobial drug controlling system used in a previous study found that it can both reduce and not reduce the consumption of antimicrobial drugs.[@b5-ijgm-10-443] However, using higher doses of the drug does not mean inappropriate use of the antimicrobial drug. Thus, there should be a process to evaluate the drug's reasonable dosage (drug use evaluation), coupled with an analysis of the antimicrobial consumption. Furthermore, there are limited studies on the antimicrobial drug controlling system in hospitals without ID consultation.

The main objective of this study was to compare the appropriateness of prescribing carbapenem before and after using antimicrobial restriction systems. Second, the study aimed to compare the amounts of antimicrobial drug in the form of prescribed dose per 1,000 bed days (defined daily dose \[DDD\]/1,000 bed days; DDD/1,000 a day), and the use of carbapenem in the average cost per patient baht (THB/person) before and after using antimicrobial restriction systems in hospitals without ID specialists.

Materials and methods
=====================

Study design and patients
-------------------------

This retrospective cross-sectional before and after study was conducted in Lamphun Hospital, a general hospital with 433 beds in the north of Thailand, to limit prescribing of carbapenem. This general hospital serves patients in Lamphun province and does not have an ID specialist service. Data were reviewed from the medical records and electronic databases of the period from September 2014 to January 2015 (before) and from September 2015 to January 2016 (after), thus began the control of antimicrobial drug use in September 2015 to assess the appropriateness of prescribing carbapenem, the amounts of antimicrobial drug in the form of prescribed dose per 1,000 bed days (DDD/1,000 bed days; DDD/1,000 a day) and the use of carbapenem in the average cost per patient baht (THB/person) before and after using an antimicrobial restriction system.

The patients were eligible for the study if they were older than 18 and received carbapenem from September 2014 to January 2015 (before) and from September 2015 to January 2016 (after). The patients were randomly selected using a simple random sampling technique. The two patient groups were selected from different time periods, during the period from September 2014 to January 2015 (before antimicrobial restriction, n=180) and from September 2015 to January 2016 (after antimicrobial restriction, n=180). The study findings were compared to the findings of the same period of the previous year that did not use any antimicrobial restriction system.

The Ethics Committee of Lamphun Hospital (LPN 51/2559) approved this study with a waiver of informed consent, as nothing beyond routine diagnostic tests, monitoring, and treatment was performed during the study (minimal risk), obtaining informed consent was impracticable, and the collected data were stored anonymously.

Process of prescribing of antimicrobial restriction system in Lamphun Hospital
------------------------------------------------------------------------------

1.  Specialty physicians prescribe the restricted antimicrobial agent initially for 3 days. They must fill in the requested antimicrobial use form and send it to the pharmacist unit, in order to restrict the dispensing of the antimicrobial drug to no more than 3 days within 24 h of the first prescription.

2.  Pharmacists evaluate the antimicrobial use by taking into consideration the appropriateness of the indications, dosage, and route of administration, and adjust the dose based on the renal function. In case of inappropriate prescription, the pharmacist consults the physician for adjustment for appropriate use.

3.  During the first 3 days of prescribing the antimicrobial drug, the internists who have been appointed by the administrator of the hospital assess the appropriateness of the antimicrobial use based on the indications, laboratory detection, and the patient's response to the treatment.

4.  After that, the pharmacist dispenses the restricted antimicrobial agent according to the advice of the authorized physician who approved the drug. The pharmacist, then, follows up on the culture and the sensitivity of the bacteria to find out if the bacteria are resistant to the restricted antimicrobial agent or sensitive to the other narrow- spectrum antibiotics. Thereafter, the pharmacist consults the authorized physician who orders the empirical restricted antimicrobial agent to be adjusted in accordance with the susceptibility of the bacteria.

Developed protocol for assessment
---------------------------------

Criteria for the appropriateness of carbapenem use have been developed by ID pharmacists, internists (internal medicine physicians) of Lamphun Hospital, and ID physicians. Also, they have been accredited by the Pharmacy and Therapeutic Committee of Lamphun Hospital.

Outcome measures
----------------

Comparison of the appropriateness of prescribing was carried out before and after using the antimicrobial restriction system. Prescribing is considered appropriate when it is able to meet all the criteria, which are as follows: Appropriate for the indication: an empiric therapy/specific therapy is prescribed for the indications provided in the restricted antimicrobial use form, and the use of empiric therapy or specific therapy modified the treatment based on data obtained from the culture and the antimicrobial susceptibility test.The appropriate dose for each patient based on the criteria defined by dose adjustment based on the patient's renal function.Inappropriate prescribing is due to either of the following characteristics: Inappropriate indication: an empiric therapy/specific therapy prescribed for which the indication criteria are not available in the restricted antimicrobial use form. In addition, the use of empiric therapy or specific therapy did not modify the treatment according to the data from the bacterial culture and the antimicrobial susceptibility test.Inappropriate dose prescribing as specified in the assessment criteria. Or the dosage in patients with renal impairment was not adjusted.The clinical response of treatment was defined by the following: Complete response: resolution of fever, leukocytosis, and local signs and symptoms of infections at the end of treatmentPartial response: partial resolution of fever, leucocytosis, and local signs and symptoms of infections at the end of treatmentFailure: failure to meet all the criteria for clinical response Empiric therapy: prescribed antibiotics against the most likely pathogens to account for those signs and symptoms of infection.

Specific therapy: the prescribed antibiotics subsequently amended when the responsible pathogen was identified and its susceptibility to antimicrobials was tested.

Amount of antimicrobial drugs
-----------------------------

The study calculated the amount of drugs in the form of prescribed dose per 1,000 bed days (DDD/1,000 day bed; DDD/1,000 bed days), the average daily volume of drug use in the indications for adult patients without indicating the correct dose of the treatment but as a unit used in comparing consumption. The formula is as follows:[@b6-ijgm-10-443] $$\text{DDD}\ \left( g \right)/1,000\ \text{day~bed} = \frac{\left( \text{amount~of~drug~in~unit~grams} \right) \times 1,000}{\text{DDD}^{*} \times \text{number~of~day~beds}}$$\*DDD is defined by the World Health Organization (WHO) for each drug: meropenem, imipenem=2 g; ertapenem=1 g.

Statistical methods
-------------------

Statistical analyses were performed using SPSS version 17. Comparison of appropriateness between prescribing before and after using the antimicrobial restriction system was performed using Fisher's exact test and chi-square test. Comparison of the amount of carbapenem in the dose prescribed per 1,000 bed days (DDD/1,000 patient days), infection per 1,000 patient days, including the use of carbapenem in the average cost per patient baht before and after using the antimicrobial restriction system, was carried out using independent *t*-test for parametric data or Mann--Whitney *U* test for nonparametric data. All test results of statistical significance were two-sided, with the significance level set at 0.05.

Multivariate analysis was performed to adjust some con-founders when we compared the outcomes between before and after period groups.

Results
=======

Patient characteristics
-----------------------

The total sample size was 360 prescriptions (before, n=180; after, n=180). The number of males was more than the number of females. Most of the patients were over 60 years of age, and the median of lengths of stay were 16 and 12 days for before and after groups, respectively ([Table 1](#t1-ijgm-10-443){ref-type="table"}).

Clinical data of patients
-------------------------

From the total of 360 prescriptions, the clinical data regarding the underlying disease, the infection site, the type of prescription, and the clinical outcome were analyzed. Investigation of data regarding before and after using the antimicrobial restriction system revealed that the most common types of infection were urinary tract infections, followed by lower respiratory tract infections ([Table 2](#t2-ijgm-10-443){ref-type="table"}).

The type of prescribing and the clinical outcomes before and after the use of the antimicrobial restriction system are shown in [Tables 2](#t2-ijgm-10-443){ref-type="table"} and [3](#t3-ijgm-10-443){ref-type="table"}.

Incidence rates of nosocomial infections due to resistant organisms
-------------------------------------------------------------------

The incidence rates of nosocomial infections caused by Enterobacteriaceae resistant to ertapenem before and after the intervention to limit antimicrobial therapy were 2.78 and 0.63 infections per 1,000 patient-days, respectively (*p*=1.000). However, the incidence rates of nosocomial infections caused by Enterobacteriaceae resistant to meropenem were 2.02 and 0.32 infections per 1,000 patient days, respectively (*p*=1.000). The incidence rates of nosocomial infections caused by Enterobacteriaceae resistant to carbapenem (CRE) were 4.80 and 0.95 infections per 1,000 patient days, respectively (*p*=1.000). The incidence rates of nosocomial infections caused by *Pseudomonas aeruginosa* resistant to meropenem were 3.53 and 1.28 infections per 1,000 patient days, respectively (*p*=1.000), as shown in [Table 4](#t4-ijgm-10-443){ref-type="table"}.

Appropriateness of prescribing
------------------------------

Out of the total of 360 prescriptions, it was observed that the number of appropriate prescribing after using the antimicrobial restriction system was higher than the number before using the antimicrobial restriction system ([Table 5](#t5-ijgm-10-443){ref-type="table"}). Inappropriate prescribing, including indication and improper dose, was found to have decreased after using the antimicrobial restriction system when compared with before using the antimicrobial restriction system ([Table 6](#t6-ijgm-10-443){ref-type="table"}).

Amount of carbapenem used in dose
---------------------------------

In all of the 360 prescriptions, as regards the amount of carbapenem in the dose prescribed per 1,000 bed days after using the antimicrobial restriction system, it was found that the amount of meropenem had increased by 7.54% after the use of the antimicrobial restriction system when compared with before the use of the antimicrobial restriction system, but it was not statistically significant ([Table 7](#t7-ijgm-10-443){ref-type="table"}). The utilization of ertapenem had decreased by 20.05% after using the antimicrobial restriction system when compared with before using the antimicrobial restriction system, but it was not statistically significant ([Table 7](#t7-ijgm-10-443){ref-type="table"}).

Expense for carbapenem
----------------------

In all of the 360 prescriptions, the expense for carbapenem in the average value of baht per patient (THB/person) was found to have significantly decreased (36.33%) after the use of the antimicrobial restriction system when compared with before the use of the antimicrobial restriction system (*p*=0.001). The values of meropenem and ertapenem were found to have significantly decreased by 30.01% and 53.90%, respectively, after using the antimicrobial restriction system when compared with their values before using the antimicrobial restriction system ([Table 8](#t8-ijgm-10-443){ref-type="table"}).

Discussion
==========

Prolonged use of broad-spectrum antimicrobial agents can lead to increase in the risk of resistant bacteria (colonization of antibiotic-resistant bacteria) and repeated incidents of infections with resistant strains (secondary infection by antibiotic-resistant bacteria); the spread of resistant bacteria in hospitals and across wards in hospitals, and subsequent consumption of antimicrobial agents, has increased. So, when information regarding the pathogen and the susceptibility test of the bacteria is available, the specific antimicrobial effect on the pathogen, or the narrow-spectrum antimicrobial drug, based on the susceptibility test, should be put to use. Moreover, dosage, duration of antimicrobial treatment, and antimicrobial tissue concentration should be appropriate according to the antibiotic stewardship program.[@b3-ijgm-10-443]

Despite the hospital chosen in this study not having ID consultation, the results show that an antimicrobial restriction system can increase the appropriateness of prescribing antibiotics. The expenditure for carbapenem was found to have decreased after using the antimicrobial restriction system when compared with before using the antimicrobial restriction system. In addition, the incidence rates of nosocomial infections caused by resistant organisms such as CRE and meropenem-resistant *P. aeruginosa* tended to decrease after using the antimicrobial restriction system. The result of this study is in contrast with the results of Phaliphot et al[@b7-ijgm-10-443] who conducted a retrospective cohort research by recruiting patients from the critical care surgical ward at Maharaj Nakorn Chiang Mai Hospital between the year 2008 (before) and the years 2009--2011 (after) and found that the rate of *P. aeruginosa* resistance to imipenem increased by about 16% after using the antimicrobial restriction system (*p*=0.011). In addition, Sistanizad et al[@b8-ijgm-10-443] studied the effect of an antimicrobial control program and found that the sensitivity of *Pseudomonas* spp. to imipenem had increased from 15.79% to 38.10% (*p*\<0.01) after using the antimicrobial restriction system. However, the sensitivity of Enterobacteriaceae to imipenem was not found to change significantly during the study period. Pakyz et al,[@b9-ijgm-10-443] in a retrospective, longitudinal, multicenter analysis, showed that the incidence rates of carbapenem-resistant *P. aeruginosa* in hospitals that restricted carbapenems were significantly low for all 5 years compared with those that did not restrict (*p*=0.01).

In this study, investigation of the appropriateness of prescribing demonstrated a statistically significant increase in carbapenem use (from 38.3% to 55.0% (odds ratio, 2.150; 95% CI, 1.351--3.423; *p*=0.001); the amount of carbapenem in DDD/1,000 patient days increased from 616.71 to 638.20 DDD/1,000 bed days (*p*=0.611) without statistical significance and the expense for carbapenem use demonstrated a statistically significant decrease over a 5-month period (from 5,030.5 to 3,202.9 THB/person; *p*=0.001). The results of this study were consistent with the findings of Ozkurt et al[@b10-ijgm-10-443] who found that the antimicrobial use decreased from 52.7% (before controlling) to 36.7% (after controlling; *p*\<0.001). The appropriateness of prescribing was observed to increase from 55.5% to 66.4% (*p*\<0.05). Similar to these, Allouch et al[@b11-ijgm-10-443] conducted a retrospective cohort study to compare antibiotic use, cost, and consumption before and after the application of the antibiotic restriction program; after using the antimicrobial restriction system, it was found that the rate of restricted antibiotic use had decreased by 11% (*p*\<0.0001) and the ratio of the cost of restricted antibiotics had decreased by 9% (*p*=0.02).

In this study, in contrast to the observations made by Gyssens et al,[@b12-ijgm-10-443] it was found that after controlling, the amount of antimicrobial drug used (DDD/100 bed days) had increased from 59.8 to 72.6 g; the appropriate prescribing was 53%, the same as that in the study of Apisarnthanarak et al[@b13-ijgm-10-443] who obtained similar results after using education and an antibiotic-control program. Inappropriate use of antimicrobial drugs had decreased (42% vs 20%; *p*\<0.001), but the amount of carbapenem used had increased (2.93 vs 3.13; DDD/1,000 a day).

In addition, the evaluation results regarding the expense for antimicrobial drug use in this study are consistent with the results of a study by Ozkurt et al[@b10-ijgm-10-443] who found that after controlling the antimicrobial drug use, the total expenditure for the antimicrobial drugs had decreased by 18.5%. The expense for the antimicrobial drug had reduced by 332,000 dollars per year. Similarly, Allouch et al[@b11-ijgm-10-443] found that the antimicrobial cost was saved by approximately US\$ 8,099 per month, and that the expenditure for all the antibiotics had decreased by 22.3% (*p*\<0.001). In addition, Rattanaumpawan et al[@b14-ijgm-10-443] found that the antimicrobial drug outlay had reduced by \~US\$ 862,704 after using the drug use evaluation protocol.

The control and prevention of antimicrobial resistance rests on hospitals, and it is up to the hospital administration to realize its importance. Moreover, the policies adopted should be adequate and effective for the control and prevention of antimicrobial resistance in hospitals. For example, health care personnel who have sufficient knowledge should be employed, and the correct and adequate resources, such as separate rooms, body protectors, alcohol gels for hand cleaning, and quality microbiology laboratories, should be present, and continuous development of the involved personnel should be followed. Thoroughly planned-out practices and dissemination practices should be followed. Additionally, the use of best practices is comprehensive, consistent, and continuous. Also, communication and coordination between the involved personnel is key to successful use of controlled antimicrobial agents even without ID specialists.[@b3-ijgm-10-443]

Limitations
===========

This study had its limitations: 1) The study had limited use of controlled antimicrobial agents. Thus, uncontrolled antimicrobial agents may have increased in use, leading to increased resistance to uncontrolled antimicrobial agents. 2) The 5-month study period may be too short to conclude the trend of using various drugs. The duration of study should be increased to 1 year (before and after antimicrobial control) in order to increase the number and variety of prescription samples included, so that the difference between the incidences of antimicrobial resistance can be detected. 3) As regards the amount of the drug (DDD) in some populations, such as patients with renal dysfunction and patients with low body weight, the value of DDD may have been underestimated.

Conclusion
==========

The study results suggest that an antimicrobial restriction system can increase the appropriateness of prescribing antibiotics. The expenditure for carbapenem was decreased after using the antimicrobial restriction system when compared with before using the antimicrobial restriction system, even without ID consultation. However, the amount of carbapenem in the dose prescribed per 1,000 bed days was not found to have reduced after the use of the antimicrobial restriction system.
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###### 

Patient characteristics

  Characteristics                     Number of prescriptions (%)   *p*-value     
  ----------------------------------- ----------------------------- ------------- -------
  Sex                                                                             
   Male                               108 (60)                      116 (64.4)    0.384
   Female                             72 (40)                       64 (35.6)     
  Age (years)                                                                     
   18--30                             3 (1.7)                       9 (5)         0.194
   31--60                             64 (35.5)                     56 (31.1)     
   \>60                               113 (62.8)                    115 (63.9)    
  Length of stay, median (min--max)   16 (1--122)                   12 (1--161)   0.001
  Wards prescribing carbapenem                                                    
   Medical ward                       150 (83.3)                    169 (93.9)    0.001
   Surgical ward                      21 (11.7)                     3 (1.7)       
   Orthopedic ward                    4 (2.2)                       4 (2.2)       
   Neurologic ward                    5 (2.8)                       3 (1.7)       
   Obstetric ward                     0 (0)                         1 (0.6)       

###### 

Clinical data of patients

  Characteristics                      Number of prescriptions (%)   *p*-value    
  ------------------------------------ ----------------------------- ------------ ---------
  Underlying disease                                                              
   Orthopedic disease                  4 (4.12)                      2 (2.67)     \<0.001
   Neurologic disease and CNS          4 (4.12)                      2 (2.67)     
   Lower respiratory tract disease     11 (11.34)                    11 (14.66)   
   Other                               78 (80.41)                    60 (80.00)   
  Type of infection                                                               
   Bone and joint infection            4 (2.20)                      2 (1.10)     \<0.001
   Lower respiratory tract infection   45 (24.20)                    48 (25.90)   
   Central nervous system infection    11 (5.90)                     3 (1.62)     
   Urinary tract infection             53 (28.60)                    49 (26.49)   
   Sepsis                              20 (10.70)                    36 (19.45)   
   Bacteremia                          13 (6.90)                     6 (3.24)     
   Skin and soft tissue infection      5 (2.70)                      2 (1.10)     
   Neutropenia                         0 (0.00)                      2 (1.10)     
   Intra-abdominal infection           16 (8.60)                     4 (2.16)     
   Septic shock                        16 (8.60)                     23 (12.43)   
   Unknown                             3 (1.60)                      10 (5.41)    

**Note:** Other: cancer, liver disease, cardiovascular disease, renal disease.

**Abbreviation:** CNS, central nervous system.

###### 

Types of prescriptions and clinical outcomes

  Parameter                  Number of prescriptions (%)   Unadjusted OR (95% CI)   *p*-value              Adjusted OR[a](#tfn3-ijgm-10-443){ref-type="table-fn"} (95% CI)   *p*-value              
  -------------------------- ----------------------------- ------------------------ ---------------------- ----------------------------------------------------------------- ---------------------- -------
  **Type of prescription**                                                          2.162 (1.417--3.300)   0.000                                                             2.329 (1.425--3.805)   0.001
  Empiric therapy            81 (45.00)                    117 (65.00)                                                                                                                              
  Specific therapy           99 (55.00)                    63 (35.00)                                                                                                                               
  **Clinical outcome**                                                              0.575 (0.178--0.973)   0.005                                                             0.594 (0.153--1.036)   0.008
  Complete response          0 (0.00)                      46 (25.60)                                                                                                                               
  Partial response           90 (50.00)                    49 (27.20)                                                                                                                               
  Failure                    90 (50.00)                    85 (47.20)                                                                                                                               

**Note:**

Adjusted for length of stay, wards, underlying disease, and type of infection.

**Abbreviations:** CI, confidence interval; OR, odds ratio.

###### 

Incidence rates of nosocomial infections caused by resistant organisms before and after using the antimicrobial restriction system

  Microorganism                      Number of infections per 1,000 patient days   *p*-value   
  ---------------------------------- --------------------------------------------- ----------- -------
  **Enterobacteriaceae**                                                                       
  Ertapenem (R) Enterobacteriaceae   2.78                                          0.63        1.000
  Meropenem (R) Enterobacteriaceae   2.02                                          0.32        1.000
  CRE                                4.80                                          0.95        1.000
  ***Pseudomonas aeruginosa***                                                                 
  Meropenem (R) *P. aeruginosa*      3.53                                          1.28        1.000

**Notes:** Before: 3,961 patient days. After: 3,132 patient days.

**Abbreviations:** CRE, Carbapenem (R) Enterobacteriaceae; R, resistant.

###### 

Appropriateness of prescribing

  Parameter                        Number of prescriptions (%)   Unadjusted OR (95% CI)   *p*-value              Adjusted OR[a](#tfn7-ijgm-10-443){ref-type="table-fn"} (95% CI)   *p*-value              
  -------------------------------- ----------------------------- ------------------------ ---------------------- ----------------------------------------------------------------- ---------------------- -------
  Appropriateness of prescribing                                                          1.966 (1.292--2.993)   0.002                                                             2.150 (1.351--3.423)   0.001
  Appropriate                      69 (38.3)                     99 (55.0)                                                                                                                                
  Inappropriate                    111 (61.7)                    81 (45.0)                                                                                                                                

**Note:**

Adjusted for length of stay, wards, underlying disease, and type of infection.

**Abbreviations:** CI, confidence interval; OR, odds ratio.

###### 

Inappropriate prescribing

  Inappropriate prescribing   Number of prescriptions (%)   Unadjusted OR (95% CI)   *p*-value              Adjusted OR[a](#tfn9-ijgm-10-443){ref-type="table-fn"} (95% CI)   *p*-value              
  --------------------------- ----------------------------- ------------------------ ---------------------- ----------------------------------------------------------------- ---------------------- -------
  Indication                  40 (22.3)                     28 (15.6)                0.800 (0.468--1.367)   0.414                                                             0.811 (0.456--1.445)   0.478
  Improper dose               88 (48.9)                     67 (37.2)                1.613 (1.060--2.456)   0.026                                                             1.879 (1.173--3.011)   0.009

**Note:**

Adjusted for length of stay, wards, underlying disease, and type of infection.

**Abbreviations:** CI, confidence interval; OR, odds ratio.

###### 

Amount of carbapenem in dose prescribed per 1,000 bed days (DDD/1,000 bed days)

  Drug                                                       Mean DDD (g)/1,000 bed days   \% difference between before and after   *p*-value   
  ---------------------------------------------------------- ----------------------------- ---------------------------------------- ----------- -------
  Carbapenem                                                 616.71                        638.20                                   +3.48       0.611
  Meropenem[\*](#tfn11-ijgm-10-443){ref-type="table-fn"}     597                           642.05                                   +7.54       0.972
  Ertapenem[\*\*](#tfn12-ijgm-10-443){ref-type="table-fn"}   761.86                        609.07                                   −20.05      0.220

**Notes:**

Mapenem^®^ (meropenem) from Siam Pharmaceutical, Bangkok, Thailand.

Invanz^®^ (ertapenem) from Merck & Co., Inc., Kenliworth, NJ, USA.

**Abbreviation:** DDD, defined daily dose.

###### 

Prescription drug expenses in average value of baht per patient

  Drug         Average value of baht per patient (min--max)   \% difference between before and after   *p*-value   
  ------------ ---------------------------------------------- ---------------------------------------- ----------- -------
  Carbapenem   5,030.5 (204.4--41,344.8)                      3,202.9 (204.4--14,766.0)                −36.33      0.001
  Meropenem    4,320.4 (204.4--35,560.4)                      3,023.8 (204.4--12,262.2)                −30.01      0.014
  Ertapenem    9,888.7 (1,968.8--41,344.8)                    4,558.5 (984.4--14,766.0)                −53.90      0.005
